leukemia

[International Journal of Hematology] Scientists investigated the optimal timing and cutoff value to ascertain the value of NPM1 mutation in measurable residual disease assessment.

[Biomarker Research] Scientists discuss the rationale for the combinational use and summarized the current data on the combinations of BTK inhibitors and venetoclax in patients with chronic lymphocytic leukemia and mantle cell lymphoma.

[Blood Advances] Scientists conducted a prospective single-center Phase II trial in which they added autologous anti-CD19 humanized binding domain T cells to ibrutinib in chronic lymphocytic leukemia patients not in complete remission despite at least six months of ibrutinib.

[AVM Biotechnology, LLC (Business Wire)] AVM Biotechnology, LLC, announced that it has been awarded a Phase II Small Business Innovation Research (SBIR) grant. This $1.6 million award from the National Institute of Diabetes and Digestive Kidney Disease will allow the company to pursue additional research in the use of AVM0703 as a monotherapy and combination therapy to reverse recent onset and established Type 1 Diabetes.

[Cell Cycle] On-target compounds specific to MCL-1 have demonstrated promising efficacy in preclinical models of breast cancer and show potential to enhance the anti-tumor effect of conventional therapies.

[Journal of Cancer Research and Clinical Oncology] Nox4 inactivation in normal HSCs and progenitor cells caused a minor reduction in HSC numbers and reconstitution capacity.